Piperidine → 5-methyl-3-[5-(piperidin-1-yl)methyl-1,2,4-oxadiazol-3-yl]-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
反応式
Cl[CH2:2][C:3]1[O:7][N:6]=[C:5]([C:8]2[N:9]=[CH:10][N:11]3[C:17]4[CH:18]=[CH:19][CH:20]=[CH:21][C:16]=4[C:15](=[O:22])[N:14]([CH3:23])[CH2:13][C:12]=23)[N:4]=1.[NH:24]1[CH2:29][CH2:28][CH2:27][CH2:26][CH2:25]1>CN(C)C=O>[CH3:23][N:14]1[C:15](=[O:22])[C:16]2[CH:21]=[CH:20][CH:19]=[CH:18][C:17]=2[N:11]2[CH:10]=[N:9][C:8]([C:5]3[N:4]=[C:3]([CH2:2][N:24]4[CH2:29][CH2:28][CH2:27][CH2:26][CH2:25]4)[O:7][N:6]=3)=[C:12]2[CH2:13]1参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
1.15 g (3.5 mmol) of 3-(5-chloromethyl-1,2,4-oxadiazol-3-yl)-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one were stirred at room temperature for 1 hour with 1 g (11.7 mmol) of piperidine and 10 ml of N,N-dimethylformamide. By evaporation of the reaction mixture and chromatography of the residue on silica gel while eluting with ethyl acetate/ethanol 9/1 there was obtained 0.98 g (74%) of 5-methyl-3-[5-(piperidin-1-yl)methyl-1,2,4-oxadiazol-3-yl]-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one of m.p. 167°-168°, which was converted into the hydrochloride.
後処理
- customBy evaporation of the reaction mixture and chromatography of the residue on silica gel
- washwhile eluting with ethyl acetate/ethanol 9/1 there
出典と根拠
- ORDレコード
- ord-63952b5395054d1187b1289f09e3208a
- 出典データセット
- uspto-grants-1997_09
- 特許番号
- US05665718
反応ノート
読み込み中…